Frontage Holdings Sets Board Meeting to Approve 2025 Results and Consider Final Dividend

Frontage Holdings Corp. ( (HK:1521) ) has issued an announcement.

Frontage Holdings Corporation has scheduled a board meeting for March 30, 2026 to review and approve its annual results for the year ended December 31, 2025. At the same meeting, the board will also consider whether to recommend a final dividend, a decision that could affect shareholder returns and signal the company’s financial performance and capital allocation priorities.

The announcement also confirms the current composition of the company’s board, listing its executive, non-executive, and independent non-executive directors. This underscores the company’s existing governance structure as it approaches the release of full-year financial results and any potential dividend proposal.

The most recent analyst rating on (HK:1521) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Frontage Holdings Corp. stock, see the HK:1521 Stock Forecast page.

More about Frontage Holdings Corp.

Frontage Holdings Corporation is a contract research organization serving the global pharmaceutical and biotech industries. The company provides research, development, and related laboratory services through its subsidiaries, supporting drug discovery and development activities for clients in various healthcare and life sciences markets.

Average Trading Volume: 170,801

Technical Sentiment Signal: Sell

Current Market Cap: HK$2.22B

Find detailed analytics on 1521 stock on TipRanks’ Stock Analysis page.